Francesca Alessandra Ambrosio

Nationality: Italian

WORK EXPERIENCE

Università degli Studi "Magna Graecia" di Catanzaro

PostDoctoral Researcher

[02/05/2024 – 30/04/2025]

Dipartimento di Scienze del Farmaco dell'Università di Pavia

Lecturer - Second Level Master's Program in "Drug Design and Development"

[2024 – Current]

Università degli Studi "Magna Graecia" di Catanzaro

PostDoctoral Researcher

[05/2022 – 11/2023]

Università degli Studi "Magna Graecia" di Catanzaro

PostDoctoral Researcher

[05/2021 – 30/04/2022]

Università degli Studi "Magna Graecia" di Catanzaro – Catanzaro, Italy

City: Catanzaro | **Country:** Italy

PostDoctoral Researcher

[04/2020 – 03/2021]

Net4Science SRL – Catanzaro, Italy

City: Catanzaro | **Country:** Italy

Researcher

[01/2020 – 03/2020]

Researcher in medicinal chemistry

Dipartimento di Farmacia e Scienze della Salute e della Nutrizione dell'Università della Calabria – Cosenza, Italy

City: Cosenza | **Country:** Italy

Seminar Lecturer - Second-Level Master's Program in "Nutrizione ed integrazione nutraceutica"

[2020 – Current]

Università degli Studi "Magna Graecia" di Catanzaro – Catanzaro, Italy

City: Catanzaro | **Country:** Italy

Teaching assistant for the disciplines related to the scientific-disciplinary sector of pharmaceutical chemistry

[2019 – 2020]

Università degli Studi "Magna Graecia" di Catanzaro – Catanzaro, Italy

City: Catanzaro | **Country:** Italy

Appointment of subject expert for SSD CHIM/08, Pharmaceutical Chemistry; CHIM/10, Food Chemistry; and CHIM/11, Fermentation chemistry

[2018 – Current]

"Parafarmacia Sascal", Aeroporto Internazionale of Lamezia Terme

Pharmacist

[08/2015 – 03/2016]

EDUCATION AND TRAINING

Experimental thesis at the Computational Chemistry Laboratory (CCLab)
Università degli Studi "Magna Graecia" di Catanzaro [06/2014 – 03/2015]

Degree in Pharmacy with vote 110/110
Università degli Studi "Magna Graecia" di Catanzaro [31/03/2015]

Enrolment in the pharmacist professional register
[26/06/2015]

City: Catanzaro | **Country:** Italy

1st Training School – MuTaLig COST Action
Universitat Wien [02/2017]

City: Vienna | **Country:** Austria

11th European Workshop in Drug Design and Mu.Ta.Lig. Training School
[05/2017]

City: Certosa di Pontignano, Siena | **Country:** Italy

Visiting PhD student
Scripps Research Institute North Torrey Pines Road, California (Stati Uniti) [08/2018 – 12/2018]

PhD in Life Sciences
Università degli Studi "Magna Graecia" di Catanzaro [03/10/2019]

National Scientific Qualification as Associate Professor for the disciplinary field of 03/D1 - Medicinal, toxicological and nutritional chemistry and applied technologies
[2024]

LANGUAGE SKILLS

Mother tongue(s): Italian

Other language(s):

English

LISTENING B2 **READING** B2 **WRITING** B2

SPOKEN PRODUCTION B2 **SPOKEN INTERACTION** B2

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

SKILLS

Microsoft Windows, MacOs, Linux, Unix

PUBLICATIONS

Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance

Malet I.; Ambrosio F.A.; Subra, F.; Herrmann, B.; Leh, H.; Bouger, M.C.; Artese, A.; Katlama, C.; Talarico, C.; Romeo, I.; Alcaro, S.; Costa, G.; Deprez, E.; Calvez, V.; Marcelin, A.G.; Delelis, O. J. Antimicrob. Chemother., 2018, 73,1158-1166

Exploration of ligand binding modes toward the identification of compounds targeting HuR: a combined STD-NMR and MolecularModelling approach.

Vasile F.; Della Volpe S.; Ambrosio F.A.; Costa G.; Unver M.Y.; Zucal C.; Rossi D.; Martino E.; Provenzani A.; Hirsch A.K.H.; Alcaro S.; Potenza D.; Collina S. Sci. Rep. 2018, 8(1), 13780.

Novel natural non- nucleoside inhibitors of HIV-1 reverse transcriptase identified by shape- and structure-based virtual screening techniques.

Costa G.; Rocca R.; Corona A.; Grandi N.; Moraca F.; Romeo I.; Talarico C.; Gagliardi M.G.; Ambrosio F.A.; Ortuso F.; Alcaro S.; Distinto S.; Maccioni E.; Tramontano E.; Artese A. Eur. J. Med. Chem., 2019, 161, 1-10.

New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).

Pouga L.; Santoro M.M.; Charpentier C.; Di Carlo D.; Romeo I.; Artese A.; Alcaro S.; Antinori A.; Wirden M.; Perno C.F.: Ambrosio F.A.; Calvez V.; Descamps D.; Marcelin A.G.; Ceccherini-Silberstein F.; Lambert-Niclot S. Chem Biol Drug Des, 2019

Novel Compounds Targeting the RNA-Binding Protein HuR. Structure- Based Design, Synthesis, and Interaction Studies

Della Volpe S.; Nasti R.; Queirolo M.; Unver M.Y.; Jumde V.K.; Domling A.; Vasile F.; Potenza D.; Ambrosio F.A.; Costa G.; Alcaro S.; Zucca C.; Provenzani A.; Di Giacomo M.; Rossi D.; Hirsch A.K.H.; Collina S. ACS Med Chem Lett, 2019, 10(4), 615-620

Computer-based techniques for lead identification and optimization I: Basics.

Maruca A.; Ambrosio F.A.; Lupia A.; Romeo I.; Rocca R.; Moraca F.; Talarico C.; Bagetta D.; Catalano R.; Costa G.; Artese A.; Alcaro, S. Physical Science Review, 2019, 4(6), 20180113

AutoDock Bias: improving binding mode prediction and virtual screening using known protein-ligand interactions.

Arcon J.P.; Modenutti C.P.; Avendano D.; Lopez E.D.; Defelipe L.A.; Ambrosio F.A.; Turjanski A.G.; Forli S.; Marti M.A. Bioinformatics, 2019, 35(19), 3836-3838.

A computer-assisted discovery of novel anti-obesity compounds as selective carbonic anhydrase VA inhibitors.

Costa G.; Carta F.; Ambrosio F.A.; Artese A.; Ortuso F.; Moraca F.; Rocca R.; Romeo I.; Lupia A.; Maruca A.; Bagetta D.; Catalano R.; Vullo D.; Alcaro S.; Supuran C.T. Eur. J. Med. Chem., 2019, 181, 111565.

The Mediterranean Diet as source of bioactive compounds with multi-targeting anti-cancer profile.

Maruca A.; Catalano R.; Bagetta D.; Mesiti F.; Ambrosio F.A.; Romeo I.; Moraca F.; Rocca R.; Ortuso F.; Artese A.; Costa G.; Alcaro S.; Lupia A. Eur. J. Med. Chem., 2019, 181, 111579.

Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrate activity.
Eur. J. Med. Chem. 2019

Esposito, F.; Ambrosio, F.A .; Maluddu, R.; Costa, G.; Rocca, R.; Maccioni, E.; Catalano, R.; Romeo, I.; Eleftheriou, P.; Karia, D.C.; Tsirides, P.; Godvani, N.; Pandya, H.; Corona, A.; Alcaro, S.; Artese, A.; Geronikaki, A.; Tramontano, E.

D3R Grand Challenge 4: prospective pose prediction of BACE1 ligands with AutoDock-GPU.

Santos-Martins, D.; Eberhardt, J.; Bianco, G.; Solis-Vasquez, L.; Ambrosio, F.A.; Koch, A.; Forli, S. J Comput Aided Mol Des, 2019, 33(12), 1071–1081.

Comparison of affinity ranking using AutoDock-GPU and MM-GBSA scores for BACE-1 inhibitors in the D3R Grand Challenge 4.

Khoury, L.E.; Santos-Martins, D.; Sasmal, S.; Eberhardt, J.; Bianco, G.; Ambrosio, F.A.; Solis-Vasquez, L.; Koch, A.; Forli, S.; Mobley, D.L. J. Comput Aided Mol Des, 2019, 33(12), 1011-1020.

Mediterranean products as promising source of multi- target agents in the treatment of metabolic syndrome.

Bagetta, D.; Maruca, A.; Lupia, A.; Mesiti, F.; Catalano, R.; Romeo, I.; Moraca, F.; Ambrosio, F.A.;Costa, G.; Artese, A.; Ortuso, F.; Alcaro, S.; Rocca, R. Eur. J. Med. Chem., 2020, 186, 111903.

Computer-based techniques for lead identification and optimization II: Advanced search methods.

Lupia, A.; Moraca, F.; Bagetta, D.; Maruca, A.; Ambrosio, F.A.; Rocca, R.; Catalano, R.; Romeo, I.; Talarico, C.; Ortuso, F.; Artese, A.; Alcaro, S. Physical Sciences reviews, 2020, 5(5), 20180114

BOPC1 enantiomers preparation and HuR interaction study. From molecular modeling to a curious DEEP-STD NMR application.

Della Volpe, S.; Listro, R.; Parafioriti, M.; Di Giacomo, M.; Rossi, D.; Ambrosio, F.A.; Costa, G.; Alcaro, S.; Ortuso, F.; Hirsch, A.K.H.; Vasile, F.; Collina, S. ACS Med. Chem. Lett., 2020,11(5): 883–888.

Dj-1 Proteoforms in Breast Cancer Cells: The Escape of Metabolic Epigenetic Misregulation.

Scumaci, D.; Olivo, E.; Fiumara, C.V.; La Chimia, M.; De Angelis, M.T.; Mauro, S.; Costa, G.; Ambrosio, F.A.; Alcaro, S.; Agosti, V.; Costanzo, F.S.; Cuda, G. Cells, 2020, 9,1968.

In Silico Identification and Biological Evaluation of Antioxidant Food Components Endowed with Human Carbonic Anhydrase IX and XII Inhibition.

Costa, G.; Maruca, A.; Rocca, R.; Ambrosio, F.A.; Berrino, E.; Carta, F.; Mesiti, F.; Salatino, A.; Trapasso, F.; Artese, A.; Alcaro, S.; Supuran, C.T. Antioxidants, 2020, 9, 775.

Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.

Artese, A.; Svicher, V.; Costa, G.; Salpini, R.; Di Maio, V.C.; Alkhatib, M.; Ambrosio, F.A.; Santoro, M.M.; Assaraf, Y.G.; Alcaro, S.; Ceccherini-Silberstein, F. Drug Resist. Updat., 2020, 53, 100721.

Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control.

Salpini, R.; Alkhatib, M.; Costa, G.; Piermatteo, l.; Ambrosio, F.A.; Di Maio, V.C.; Scutari, R.; Duca, l.; Berno, G.; Fabeni, l.; Alcaro, S.; Ceccherini-Silberstein, F.; Artese, A.; Svicher, V. J. Antimicrob. Chemother. 2021, 76(2): 396-412.

Identification of compounds targeting HuD. Another brick in the wall of neurodegenerative disease treatment.

Ambrosio, F.A.; Coricello, A.; Costa, G.; Lupia, A.; Micaelli, M.; Marchesi, N.; Sala, F.; Pascale, A.; Rossi, D.; Vasile, F.; Alcaro, S.; Collina, S. J Med Chem, 2021, 64 (14), 9989-10000.

Anti-multiple myeloma potential of secondary metabolites from hibiscus sabdariffa—part 2

Malacrida, A.; Cavalloro, V.; Martino, E.; Costa, G.; Ambrosio, F.A.; Alcaro, S.; Rigolio, R.; Cassetti, A.; Miloso, M.; Collina, S. Molecules, 2021, 26, 6596.

SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021.

Alkhatib, M.; Svicher, V.; Salpini, R.; Ambrosio, F.A.; Bellocchi, M.C.; Carioti, l.; Piermatteo, l.; Scutari, R.; Costa, G.; Artese, A.; Alcaro, S., Shafer, R.; Ceccherini-Silberstein, F. Microbiology Spectrum, 2021, 9, 3.

Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.

Alkhatib, M.; Salpini, R.; Carioti, L.; Ambrosio, F.A.; D'Anna, S.; Duca, L.; Costa, G.; Bellocchi, M.C.; Piermatteo, L.; Artese, A.; Santoro, M.M.; Alcaro, S.; Svicher, V.; Ceccherini-Silberstein, F. Microbiology Spectrum, 2022, 10.

From Nature to Synthetic Compounds: Novel 1(N),2,3 Trisubstituted-5-oxopyrrolidines Targeting Multiple Myeloma Cells.

Listro, R.; Malacrida, A.; Ambrosio, F.A.; Rossino, G.; Di Giacomo, M.; Cavalloro, V.; Garbagnoli, M.; Linciano, P.; Rossi, D.; Cavaletti, G.; Costa, G.; Alcaro, S.; Miloso, M.; Collina, S. Int. J. Mol. Sci. 2022, 23, 13061.

Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach.

Romeo, I.; Ambrosio, F.A.; Costa, G.; Corona, A.; Alkhatib, M.; Salpini, R.; Lemme, S.; Vergni, D.; Svicher, V.; Santoro, M.M.; Tramontano, E.; Ceccherini-Silberstein, F.; Artese, A.; Alcaro, S. Molecules 2022, 27, 7522.

Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.

Ambrosio, F.A.; Costa, G.; Gallo Cantafio, M.E.; Torcasio, R.; Trapasso, F.; Alcaro, S.; Viglietto, G.; Amodio, N. Molecules 2023, 28, 1438.

Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands.

Dichiara, M.; Ambrosio, F.A.; Barbaraci, C.; González-Cano, R.; Costa, G.; Parenti, C.; Marrazzo, A.; Pasquinucci, L.; Cobos, E.J.; Alcaro, S.; Amata. ACS Chem. Neurosci. 2023, 14, 10, 1845–1858.

In Silico-Guided Rational Drug Design and Synthesis of Novel 4-(Thiophen-2-yl)butanamides as Potent and Selective TRPV1 Agonists.

Romeo, I.; Brizzi, A.; Pessina, F.; Ambrosio, F.A.; Aiello, F.; Belardo, C.; Carullo, G.; Costa, G.; De Petrocellis, L.; Frosini, M.; Luongo, L.; Maramai, S.; Paolino, M.; Moriello, A.S.; Mugnaini, C. et al. J Med Chem. 2023 66(10):6994-7015.

Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an In Silico Drug Repurposing Approach.

Ambrosio, F.A.; Costa, G.; Romeo, I.; Esposito, F.; Alkhatib, M.; Salpini, R.; Svicher, V.; Corona, A.; Malune, P.; Tramontano, E.; Ceccherini-Silberstein, F.; Alcaro, S.; Artese, A. J. Chem. Inf. Model. 2023, 63, 11, 3601–3613.

Short- and Long-Term Regulation of HuD: A Molecular Switch Mediated by Folic Acid?

Marchesi, N.; Linciano, P.; Campagnoli, L.I.M.; Fahmideh, F.; Rossi, D.; Costa, G.; Ambrosio, F.A.; Barbieri, A.; Collina, S.; Pascale, A. Int. J. Mol. Sci. 2023, 24, 12201.

Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity.

Dichiara, M.; Ambrosio, F.A.; Lee, S.M.; Ruiz-Cantero, M.C.; Lombino, J.; Coricello, A.; Costa, G.; Shah, D.; Costanzo, G.; Pasquinucci, L.; Son, K.N.; Cosentino, G.; González-Cano, R. et al. J Med Chem. 2023, 66(16):11447-11463.

Molecular and Structural Aspects of Clinically Relevant Mutations of SARS-CoV-2 RNA-Dependent RNA Polymerase in Remdesivir-Treated Patients.

Gratteri, C.; Ambrosio, F.A.; Lupia, A.; Moraca, F.; Catalanotti, B.; Costa, G.; Bellocchi, M.; Carioti, L.; Salpini, R.; Ceccherini-Silberstein, F.; Frazia, S.; Malagnino, V. et al. Pharmaceuticals. 2023 16(8):1143.

Identification of HuR-RNA Interfering Compounds by Dynamic Combinatorial Chemistry and Fluorescence Polarization.

Della Volpe, S.; Listro, R.; Ambrosio, F.A.; Garbagnoli, M.; Linciano, P.; Rossi, D.; Costa, G.; Alcaro, S.; Vasile, F.; Hirsch, A.K.H.; Collina, S. ACS Med Chem Lett. 2023, 14, 1509-1516

New Insights for Polyphenolic Compounds as Naturally Inspired Proteasome Inhibitors.

Marchese, E.; Gallo Cantafio, M.E.; Ambrosio, F.A.; Torcasio, R.; Valentino, I.; Trapasso, F.; Viglietto, G.; Alcaro, S.; Costa, G.; Amodio, N. Pharmaceuticals. 2023, 16(12):1712.

Neurodegeneration: can metabolites from Eremurus persicus help?

Cavalloro, V.; Marchesi, N.; Linciano, P.; Rossi, D.; Campagnoli, L.I.M.; Fossati, A.; Ahmed, K.M.; Malacrida, A.; Miloso, M.; Mazzeo, G.; Abbate, S.; Longhi, G.; Ambrosio, F.A.; Costa, G.; Alcaro, S. et al. Front Pharmacol. 2024;15:1309766.

Peptide Nucleic Acids in Saturation Transfer Difference Nuclear Magnetic Resonance Experiments: A Simple and Valuable Tool for Studying HuR−Small Molecule Complexes

Gado, I.; Garbagnoli, M.; Ambrosio, F.A.; Listro, R.; Parafioriti, M.; Cauteruccio, S.; Rossi, D.; Linciano, P.; Costa, G.; Alcaro, S.; Vasile, F.; Collina. S. ACS Omega 2024, 9, 45147−45158

Discovery of pyridoquinoxaline-based new P-gp inhibitors as coadjutant against Multi Drug Resistance in cancer

Ibba, R.; Sestito, S.; Ambrosio, F.A.; Marchese, E.; Costa, G.; Fiorentino , F.P.; Fusi, F.; Marchesi, I.; Polini, B.; Chiellini, G.; Alcaro, S.; Piras, S.; Carta, A.; European Journal of Medicinal Chemistry, 2024, (276) 116647

Development of selective sigma-1 receptor ligands with antiallodynic activity: A focus on piperidine and piperazine scaffolds

Cosentino, G.; Dichiara, M.; Ambrosio, F.A.; Leotta, C.G.; Costa, G.; Procopio, F.; Costanzo, G.; Raffa, A.; Artacho-Cordon, A.; Ruiz-Cantero, M.C.; Pasquinuccia, L.; Marrazzo, A.; Pitari, G.M.; Cobos, E.J.; Alcaro, S.; Amata, E. Eur. J Med Chem 2025

O-derivatization of natural tropolone and β-thujaplicin leading to effective inhibitors of human carbonic anhydrases IX and XII

Journal Name: European Journal of Medicinal Chemistry 290 (2025) 117552

Melfi,F.; D'Agostino,I.; Carradori,S.; Carta,F .; Angelic,A.; Costa,G.; Renzi,G.; Ciko,A.; Vullo,D.; Resetar,J.; Ferraroni,M.; Baroni,C.; Mancuso,F.; Gitto,R.; Ambrosio,F.A.; Marchese,E.; Torcasio,R.; Amodio,N.; Capasso,C.; Alcaro,S.;Supuran, C.T.

Rosmarinus officinalis L. as Fascinating Source of Potential Anticancer Agents Targeting Aromatase and COX-2: An Overview

Gargano, A.; Greco, I.; Lupia, C.; Alcaro, S.; Ambrosio, F.A. Molecules 2025, 30, 1733

NETWORKS AND MEMBERSHIPS

[13/06/2019 – 15/06/2019] Catanzaro
Member of Organizing Committee for Paul Ehrlich Euro-PhD Network & MuTaLig COST Action meeting 2019

DRIVING LICENCE

Driving Licence: B

CONFERENCES AND SEMINARS

[28/09/2016 – 03/10/2016] Pula, Cagliari, Italy.
3rd innovative approaches for novel antiviral agents summer school.
In silico identification of new natural ligands as potential HIV-1 integrase agents.

[21/05/2017 – 26/05/2017] Siena, Italy
11th EWDD European workshop in drug design & Mu.Ta.Lig training school (XI EWDD).
Analysis of new allosteric pockets on the HIV-1 integrase and hit identification of novel selective ligands by virtual screening techniques.

[22/09/2017 – 24/09/2017] Porto, Portugal
Epichembio (cm1406) and Mutalig cost (ca15135) actions joint meeting university of porto.
Cabotegravir, a new integrase inhibitor: drug stability evaluation

[03/11/2017 – 04/11/2017] Cosenza, Italy
International workshop CAT-ICBCS 2017 catalysis with ions, complexes, biological systems, clusters and surfaces.
In silico identification of chikungunya virus nsp2 protease inhibitors from natural sources.

[03/11/2017 – 04/11/2017] Cosenza, Italy
International workshop CAT-ICBCS 2017 catalysis with ions, complexes, biological systems, clusters and surfaces.
Dynophores: a molecular dynamics pharmacophore approach to identify telomerase ten domain promising binders.

[15/03/2018 – 16/03/2018] Tenerife, Spain
2nd WG Meeting – status of WG activities of the Mutalig Cost action.
In silico approaches for antiviral multi-target drugs discovery.

[23/02/2019 – 24/02/2019] Paris, France
Mutalig cost action, 3rd WG-Meeting 2019.
Exploration of ligand binding modes towards the identification of compounds targeting HuR: a combined STD-NMR and molecular modelling approach.

[13/06/2019 – 15/06/2019] Catanzaro, Italy.

Paul Ehrlich Euro-PhD Network & Mutalig Cost Action Meeting 2019
Compounds targeting the RNA-binding protein HuR. Structure-based design, synthesis and interaction studies

[14/11/2019 – 17/11/2019] Parma, Italy.
Carbonic anhydrases 2019 - the IV Satellite Meeting
In-silico approaches for anticancer multi-target drug discovery.

[22/07/2020 – 24/07/2020]
Italian Young Medinal Chemistry Virtual Meeting, 22-24 July 2020.
Preparation and HuR interaction studies of BOPC1 enantiomers combining deep-STD NMR and molecular modeling analysis

[25/02/2021 – 27/02/2021]
18th Hellenic Symposium on Medicinal Chemistry, online symposium.
Identification of natural antioxidants endowed with human carbonic anhydrase IX and XII inhibition.

[17/10/2022 – 19/10/2022] Naples, Italy
Autumn Meeting for Young Chemists in Biomedical Sciences - AMYC-BIOMED 2022
Virtual Screening studies for the discovery of new proteasome inhibitors

[02/12/2024 – 03/12/2024] Messina, Italy
Convegno Congiunto delle Sezioni Sicilia e Calabria 2024 – SCISiCa2024
In silico-guided discovery of novel Sortase A Inhibitors

HONOURS AND AWARDS

[26/07/2021] Paul Ehrlich MedChem Euro-PhD Network certificate for the excellence of Doctoral Thesis
PhD Award of excellence - Paul Ehrlich Award

[28/07/2021] Paul Ehrlich (PE) Euro - PhD Network virtual meeting
Runner-Up best oral Communication

[10/2022]
Winner of the Pharmaceutical Chemistry Division Scholarship - AMYCBIOMED 2022
Scholarship awarded for participation in the conference *"Autumn Meeting for Young Chemists in Biomedical Sciences" (AMYC - BIOMED)* 2022
Naples, October 17-19, 2022.

[10/2022] Autumn Meeting for Young Chemists in Biomedical Sciences (AMYC - BIOMED) 2022
Best Poster Presentation
Naples, October 2022.

[12/2022] Award for Outstanding Young Researchers in the Field of Chemical Sciences
Premio Bernardino Telesio 2021
Congresso Congiunto Sicilia - Calabria 1-2 December 2022

ORAL COMMUNICATION

Pathway involving the n155h mutation in hiv-1 integrase leads to dolutegravir resistance.

7th meeting of the Paul Ehrlich MedChem Euro-PhD Network. 25-27, August 2017 Vienna, University of Technology, Vienna-Austria

Induced fit docking protocol applied to the in silico evaluation of antiviral hiv-1 integrase resistance

2nd WG meeting – Status of WG actvities of the MuTaLig COST Action. 15- 16 March 2018, Instituto Universitario de Bio-Orgánica "Antonio González", Universidad de La Laguna, Tenerife-Spain.

A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase va inhibitors.

VI Congresso della Divisione di ChimicaTeorica e Computazionale della Società Chimica Italiana. 19-20 September 2019, Università della Calabria, Cosenza, Italy.

Molecular modeling studies on antiviral targets: drug resistance mechanisms and rational drug design

MedChem 2021 - PaulErlich Virtual Meeting, July 26th-28th, 2021.

Targeting HuD with Natural Compounds - Invited Speaker

NANOINNOVATION 2021, 21-24 September 2021, Rome.

[01/12/2022 – 02/12/2022]

Another brick in the wall of cancer and neurodegenerative diseases targeting ELAV family members: HuR and HuD

Convegno Congiunto 2022 delle Sezioni Calabria e Sicilia della Società Chimica Italiana "SCICaSi2022", Reggio Calabria 1-2 December 2022.

EDITOR ROLES

[2021 – Current]

REVIEW EDITOR for the journal Frontiers in Pharmacology (ISSN: 1663-9812) section "Experimental Pharmacology and Drug Discovery" .

Title of the Special Issue: "Exploring Natural Metabolites to Identify Novel Potential Therapeutic Agents"

[2022 – 2024]

GUEST EDITOR for the journal "Pharmaceuticals" (ISSN: 1424-8247).

COVER ISSUE

[2021]

Journal of Medicinal Chemistry, July 22, 2021 Volume 64, Issue 14 Pages 9577-10512.

Identification of Compounds Targeting HuD. Another Brick in the Wall of Neurodegenerative Disease Treatment.

[2023]

Journal of Chemical Information and Modeling, June 12, 2023 Volume 63, Issue 11 Pages 3227-3628.

Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an In Silico Drug Repurposing Approach.

[2023]

ACS Medicinal Chemistry Letters, November 9, 2023 Volume 14, Issue 11 Pages 1483-1602.

Identification of HuR−RNA Interfering Compounds by Dynamic Combinatorial Chemistry and Fluorescence Polarization.

COMMUNICATION AND INTERPERSONAL SKILLS

Excellent communicative skills. I work very well in team